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Abstract
Background Muscle wasting from chronic kidney disease (CKD) or from defective insulin signalling results in morbidity and,
ultimately, mortality. We have identiﬁed an endogenous mediator of insulin resistance, signal regulatory protein alpha (SIRPα),
which leads to cachexia in mice and is associated with cachexia in patients with CKD.
Methods We assessed insulin signalling and mechanisms causing muscle atrophy plus white adipose tissue (WAT) metabolism
in mouse models of CKD or acute diabetes (streptozotocin treatment). We then examined these factors in mice with global
knockout (KO) of SIRPα and sought mediators of metabolic responses in muscle and adipose tissues of mice with either
muscle-speciﬁc or adipose tissue-speciﬁc KO of SIRPα. Metabolic responses were conﬁrmed in primary cultures of adipose cells.
Results In mice with CKD, SIRPα expression was increased in WAT (three-fold, P < 0.05), and this was associated with pre-
cursors of cachexia: ‘pathologic browning’, thermogenesis, and a two-fold activation of protein kinase A (P < 0.05 vs. control
mice) plus loss of adipose tissue mass. In contrast, mice with SIRPα global KO and CKD or acute diabetes experienced improved
insulin signalling and activation of pAkt plus ‘physiologic browning’ of WAT. These mice avoided losses of muscle and adipose
tissues and experienced a 31% improvement in survival (P < 0.05) than did wild-type mice with CKD. In muscle-speciﬁc SIRPα
KO mice with CKD, we uncovered that serum SIRPα levels (P < 0.05) were suppressed and were associated with improved
insulin signalling both in skeletal muscles and in WAT. These changes were accompanied by physiologic WAT browning. How-
ever, in adipose-speciﬁc SIRPα KO mice with CKD, levels of serum SIRPα were increased over two-fold (P < 0.05), while muscle
losses were minimally inhibited. Clinical implications of SIRPα signalling are suggested by our ﬁndings that include increased
SIRPα expression in muscle and adipose tissues (P < 0.05 vs. healthy controls) plus higher SIRPα levels in the serum of patients
with CKD (2.4-fold, P=0.000017 vs. healthy controls).
Conclusions Our results show that SIRPα plays an important role as an anti-insulin mediator regulating pathways to cachexia.
In muscle-speciﬁc SIRPα KO, changes in SIRPα serum levels seem to improve insulin signalling in muscle and WAT, suggesting
crosstalk between muscle and adipose tissue. Therefore, targeting SIRPα may prevent cachexia in patients with CKD or acute
diabetes.
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Background
Losses of muscle and adipose tissues occur commonly in pa-
tients with chronic kidney disease (CKD) and are associated
with increased morbidity and mortality. For example, results
from a National Institutes of Health (NIH)-supported,
multicentre, clinical trial of haemodialysis patients carried
out over 2.5 years revealed that haemodialysis increased
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mortality by >46%.1 The authors concluded that decreases
in muscle mass and adipocytes were linked to anthropomet-
ric evidence of cachexia with low values of body mass index,
triceps skin-fold thickness, and mid-arm muscle
circumference.1
These results prompted us to investigate mechanisms that
could explain how CKD stimulates losses of both muscle and
adipose tissues. In rodent models of CKD, several mecha-
nisms have been linked to the development of protein catab-
olism, namely, inﬂammation, metabolic acidosis, insulin
resistance, glucocorticoids, and myostatin (MSTN) expres-
sion.2–8 These catabolic conditions activate caspase-3 and
the ubiquitin–proteasome system (UPS), which develop loss
of muscle proteins.9 In contrast, mechanisms causing loss of
adipose tissues in CKD are not so well characterized. This
prompted us to identify mechanisms responsible for losses
of lipid stores in CKD because patients with advanced CKD
lose adipose as well as protein stores.1 We also studied mech-
anisms causing loss of both adipocytes and muscle because
they could lead to the design of therapies for combating
the development of cachexia.
As insulin resistance is detectable early in the course of
CKD and is associated with losses of muscle and adipose
tissues, we investigated how impaired insulin signalling could
affect CKD-induced cachexia.10 We have identiﬁed a post-
insulin receptor mechanism that underlies the development
of insulin resistance: it arises from dephosphorylation of
phospho-tyrosines in insulin receptors and insulin receptor
substrate 1 (IRS1).11 In cultured muscle cells, dephosphoryla-
tion of tyrosines in the insulin receptor and IRS1 activates
speciﬁc E3 ubiquitin ligases of the UPS resulting in IRS1 deg-
radation and interruption of intracellular insulin signalling.2
In pursuing these ﬁndings, we identiﬁed a novel mediator of
insulin resistance in mice with CKD, the signal regulatory
protein alpha (SIRPα), a membrane glycoprotein that inter-
acts with SHP-1 and SHP-2, tyrosine phosphatases, dephos-
phorylating insulin receptor and IRS1.12–14 This disruption of
insulin signalling accelerates muscle proteolysis.12 In the pres-
ent experiments, we evaluated the inﬂuence of SIRPα in vivo
as a mediator of catabolic responses (i.e. sympathetic activa-
tion) that reduce adipose and muscle tissues and, hence, pro-
mote the development of cachexia.
Methods
Reagents and antibodies
Mouse Intact (1-84) parathyroid hormone (PTH) enzyme-
linked immunosorbent assay (ELISA) assay kit was purchased
from ALPCO (Salem, NH), calcium assay kit was from Cayman
(Ann Arbor, MI), protein kinase A (PKA) kinase activity kit was
from Enzo (Farmingdale, NY), Ultrasensitive Mouse Insulin
ELISA Kit was from Crystal Chem (Elk Grove Village, IL), and
Tyrosine Phosphatase Assay System was from Promega
(Madison, WI). Mouse SIRPα ELISA kit was from EIAab Science
Co. Ltd (Wuhan, China) and Human SIRPα ELISA kit from
LifeSpan Biosciences (Seattle, WA). RNeasy Lipid Tissue Mini
Kit, RNeasy Fibrous Tissue Mini Kit, and RNase-Free DNase
Set were from Qiagen (Valencia, CA); iScript cDNA Synthesis
Kit was from Bio-Rad (Hercules, CA). Phosphatase inhibitor
and protease inhibitor were from Roche (Indianapolis, IN).
TRIzol was from Life Technologies (Carlsbad, CA); RIPA lysis
and extraction buffer was from G-Biosciences (Louis, MO);
and Pierce BCA Protein Assay was from Thermo Fisher
Scientiﬁc (Rockford, IL). Streptozotocin (STZ), noradrenaline
bitartrate (NE), forskolin (FSK), and insulin were from Sigma-
Aldrich (St. Louis, MO); and 666-15 was from EMD Millipore
(Burlington, MA), and H89 and LY294002 were from Tocris
(Minneapolis, MN). Green ﬂuorescent protein (GFP) plasmid
was from Lonza (Allendale, NJ); SIRPα plasmid cDNA was
from Open Biosystems (Lafayette, CO); DMEM/F12 and
foetal bovine serum (FBS) were from Cellgro Mediatech
(Manassas, VA). The antibodies against SIRPα (#13379),
p-Akt (Ser473, #4060), Akt (#2920), PPARγ (#2443), UCP-1
(#14670), phosphorylated-hormone sensitive lipase (pHSL;
#4126), phosphorylated cAMP response element-binding pro-
tein (pCREB; #9198), phosphorylated PKA (pPKA; #9624),
GLUT4 (#2213), and GAPDH (#5174) were from Cell Signaling
Technology (Beverly, MA). Antibody against phosphotyrosine
(4G10, #05-321) was from Millipore (Temecula, CA). IRS-1
(sc-7200) was from Santa Cruz Biotechnology (Dallas, TX).
The antibody against UCP1 (#ab10983) for immunohisto-
chemical staining was from Abcam (Cambridge, MA).
Animal studies
We studied 8- to 10-week-old male mice in protocols ap-
proved by the Institutional Animal Care and Use Committee
of Baylor College of Medicine (BCM). Mice were maintained
in 12 h light/dark cycles (6 a.m. to 6 p.m.) at 24°C and fed
diets of standard or high-protein (40%) rodent chow.
C57BL/6 mice were purchased from Jackson Laboratory
(Bar Harbor, ME, USA). SIRPα Mt mice (Exons 7 and 8 were
replaced with a neomycin selection cassette) sperm were
obtained from Riken (Saitama, Japan) and backcrossed over
ﬁve generations on C57BL/6 background. The BCM
Genetically Engineered Mouse Core obtained the mouse from
cryopreserved sperm. SIRPαﬂ/ﬂ (Tm1C) mice were obtained in
conjunction with the BaSH EUCOMM.15 Skeletal muscle-
speciﬁc SIRPα knockout (KO; mSIRPα/) or adipose-speciﬁc
mice (AD-SIRPα/) with deletion of Exons 3 and 4 were gen-
erated using a Cre [muscle creatine kinase-Cre or Adipoq-Cre
mice, respectively, from Jackson Laboratory (Bar Harbor, ME,
USA)] recombinase:loxP system as previously described15;
both are on C57BL/6 background. These mice appear to have
grossly normal phenotype.
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Chronic kidney disease model
To create mice with CKD, male C57BL/6 and SIRPαMt mice at
8 weeks of age were anaesthetized, and a subtotal nephrec-
tomy was performed.5 Wild-type (WT) vs. SIRPα Mt ± CKD
mice were provided either standard rodent chow or SIRPαﬂ/ﬂ
vs. mSIRPα/ or AD-SIRPα/ ± CKD were treated with
high-protein diet (40%) to create mice with blood urea nitro-
gen (BUN) and PTH values similar to those of patients with
advanced CKD. BUN was measured in blood collected from
the tail vein. At post-surgery Weeks 14 to 16, blood from
anaesthetized mice was removed by perfusing phosphate-
buffered saline (PBS) into the left ventricle. The skeletal mus-
cles [gastrocnemius, tibialis anterior (TA), extensor digitorum
longus (EDL), and soleus] plus abdominal adipose tissues
(inguinal and visceral adipose tissues) and other organs were
removed, weighed, and immediately frozen in liquid nitrogen
and maintained at 80°C until examined.
Lipids from livers were isolated from frozen tissues by
extracting with CHCl3:CH3O:H2O, followed by drying of the or-
ganic phase under N2. Serum triglycerides and cholesterol
were assessed by kit from Abcam (Cambridge, MA). Tyrosine
Phosphatase Assay System
Glucose and insulin tolerance tests
Glucose tolerance test (GTT) and insulin tolerance test (ITT)
were performed at 9 and 10 weeks post-surgery using an Ad-
vanced Glucose Meter (Woonsocket, RI). For GTT, mice
fasted for 16 h were injected intraperitoneally with 1.5 g/kg
glucose; and tail vein blood was collected at 0, 30, 60, 90,
and 120 min intervals to assess blood glucose concentration.
For ITT, mice fasted for 4 h were injected intraperitoneally
with 0.75 units/kg insulin; and blood was collected at 0, 15,
30, 60, and 90 min intervals to measure blood glucose
concentration.
Whole-body energy metabolism test
At post-surgery Week 11, lean and fat mass of individual mice
were quantiﬁed using an X-ray Imager (PIXImus Body Compo-
sition, Lunar Corp). Whole-body energy metabolism of the
mice was assessed in the metabolic cages at post-surgery
Week 12 using a Comprehensive Lab Animal Monitoring
System (CLAMS, Columbus Instruments) in the Mouse
Phenotyping Core at BCM. CLAMS cages were housed in
temperature-controlled environmental chambers at 23°C on
a standard 12 h light/dark cycles for the duration of the
study. Animals were monitored for 24 h, and during that
time, food and water were provided ad libitum. Parameters
monitored include VO2, VCO2, respiratory exchange ratio
(RER), heat, physical activity, and food/water consumption.
Streptozotocin model
To induce acute diabetes, 12-week-old C57BL/6 and SIRPαMt
male mice were injected intraperitoneally with two doses of
150 mg/kg/day STZ in PBS.8 Control mice received the vehicle
(PBS) only. Mice were housed and fed a normal chow for 8
days. Basal insulin level (Ultrasensitive Mouse Insulin ELISA
Kit) and blood glucose were checked using serum of tail vein
blood after 4 h of fasting at Day 7. The mice were harvested
at Day 8.
Grip strength
Forelimb grip strength of CKD mice was assessed (at Week
12) and STZ mice (at Day 6). Each mouse was pulled back-
wards away in a straight, horizontal line to display peak force
obtained by a transducer (Model DFS II; Chatillon).
Noradrenaline bitartrate treatment on mice
Mice received intraperitoneal injections of NE (1mg/kg). Con-
trol mice received the vehicle. At the end of the treatment, all
mice were euthanized and harvested following heart perfu-
sion with PBS.
Primary cultures of white adipocyte
Inguinal fat pads were obtained from 5- to 6-month-old male
mice. Inguinal fat tissue was dissected gently from the skin
and washed twice in PBS. The fat tissue was minced into 1
to 3 mm2 pieces followed by digestion, then ﬁltered through
a 100 and then 40 μm cell strainer, and resuspended in
preadipocyte medium (DMEM/F12 containing 10% FBS and
1% penicillin/streptomycin). The mixture was plated in the
six-well format. Inguinal cells were grown to conﬂuency and
then treated by induction medium (1.5 μg/mL insulin, 1 μM
dexamethasone, 500 μM IBMX, and 1 μM rosiglitazone in
the preadipocyte medium). Three days after induction, cul-
tured cells were maintained in medium (1.5 μg/mL insulin
in the preadipocyte medium). At Day 8, the cells were treated
after 2 h serum starvation with PI3K inhibitor LY294002 (50
μM for 30 min or 6 h). Activation of PKA by NE (100 nM for
30 min or 6 h), H89, a PKA inhibitor (50 μM for 30 min or 6
h), and insulin (1 nM for 10 min). After treatment, protein
was extracted from cells and stored at 80°C.
3T3-L1 cell treatment
3T3-L1 cells was purchased from American Type Culture Col-
lection (Manassas, VA) and cultured in preadipocyte media in
5% CO2 in a humidiﬁed incubator at 37°C. At 80% conﬂuence,
the cells were serum starved for 2 h and treated with pCREB
activator FSK (10 μM for 24 h) or pCREB inhibitor, 666-15 (50
nM for 24 h). Subsequently, cellular proteins were extracted
and stored at 80°C. Electroporation was performed with
the Neon Transfection System (Invitrogen, Carlsbad, CA).
3T3-L1 cells (106) were electroporated with 3 μg GFP control
or 3 μg SIRPα plasmid. The cultured cells were maintained in
DMEM/F12 containing 10% FBS for 24 h.
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Reverse transcription–quantitative polymerase
chain reaction
Total RNA of fat and muscle was extracted using TRIzol and
puriﬁed with RNeasy Lipid Tissue Mini Kit and RNeasy Fibrous
Tissue Mini Kit, respectively. First-strand cDNA was synthe-
sized from 1 μg DNase-treated total RNA using Reverse Tran-
scription Supermix for reverse transcription–quantitative
polymerase chain reaction (RT–qPCR). The mRNA levels were
evaluated by qPCR using SYBR Green Supermix. Reactions of
qPCR were performed in 96-well format using a CFX96™
Real-Time System (Bio-Rad, Hercules, CA). The reaction vol-
ume was 10 μL, including 5 μL SYBR Green Supermix, 2 μL
2.5 μM primer, and 1 μL cDNA. The following thermal cycling
proﬁle was used: 95°C 3 min; 40 cycles of 95°C for 15 s, 60°C
for 30s; followed by 55°C to 95°C increment for dissociation
curve analysis. The relative mRNA levels were calculated
using the comparative CT Method (Livak and Schmittgen,
2001) and normalized to GAPDH mRNA. Sequence informa-
tion of mouse primers is as follows: GAPDH-F: 5′-TGTGAT
GGGTGTGAACCACGAGAA-3′, R: 5′-CATGAGCCCTTCCACAATG
CCAAA-3′; SIRPα-F: 5′-CTCTGTGGACGCCTGTAA-3′, R: 5′-GATG
CTGCGTCGTTTGTT-3′; IL-6 F: 5′-GAGGATACCACTCCCAACAGA
CC-3′, R: 5′-AAGTGCATCATCGTTGTTCATACA-3′; MuRF1 F: 5′-
GGGTAAAGAAGAACACCAATG-3′, R: 5′-GAAGACACACTTCCCT
ATTG-3′; Atrogin-1 F: 5′-CTGAAAGTTCT-TGAAGACCAG-3′, R:
5′-GTGTGCATAAGGATGTGTAG-3′; MSTN F: 5′-CTATAAGACAA
CTTCTGCCAAG-3′, R: 5′-AGAAAGTCAGACTCTGTAGG-3′; UCP1
F: 5′-CTTTTTCAAAGGGTTTGTGG-3′, R: 5′-CTTATGTGGTACAAT
CCACTG-3′; PGC1α F: 5′-CACATACAAG-GGAGAATTGC-3′, R:
5′-TCCTCTTCAAGATCCTGTTAC-3′; CIDEA F: 5′-CTATAACA
GAGAGCAGGGTC-3′, R: 5′-GTGTTAAGGAAT-CTGCTGAG-3′;
ATG12 F: 5′-CTCTATATGAGTGTTTTGGCAG-3′, R: 5′-TTGATAG
TAAGTCTCTTCCCAC-3′; BECN1 F: 5′-CAATAATTTCA
GACTGGGTCG-3′, R: 5′-ATTTGTCTGTCAGAGACTCC-3′; LC3 F:
5′-TGAACAAAGAGTGGAAGATG-3′, R: 5′-GCCGTCT-GATTAT
CTTGATG-3′; P62 F: 5′-AATGTGATCTGTGATGGTTG-3′, R: 5′-
GAGAGAAGCTATCAGAGAGG-3′. Sequence information of
human primers is as follows: GAPDH-F: 5′-CTTTTGCGT
CGCCAG-3′, R: 5′-TTGATGGCAACAATATCCAC-3′; SIRPα F: 5′-
GAACGGAACATCTATATTGTGG-3′, R: 5′-CATGCAACCT-
TGTAGAAGAAG-3′; UCP1 F: 5′-ACAGCACCTAGTTTAGGAAG-3′,
R: 5′-CTGTACGCATTATAAGTCCC-3′; IL-6 F: 5′-GCAGAAAAA
GGCAAAGAATC-3′, R: 5′-CTACATTTGCCGAAGAGC-3′; MuRF1
F: 5′-GACAGATGAGGAAGAGGAAG-3′, R: 5′-TCATTCATCC
AGCTCCTTAC-3′; Atrogin-1 F: 5′-AACTCAGTATTTC-CACCAAG-
3′, R: 5′-GAAGTCCAGTCTGTTGAAAG-3′.
Western blots
We homogenized 100 mg fat tissue (or 30 mg muscle tissue)
for 1 min in 300 μL cold RIPA buffer supplemented with pro-
tease and phosphatase inhibitor cocktails. The homogenates
were incubated on ice for 10 min and then centrifuged
(15,600 g) at 4°C for 15 min. The supernatants were used
as whole cell lysates. Protein concentration was determined
by Pierce BCA Protein Assay. An equal amount of protein
(50–80 μg) was separated on sodium dodecyl sulfate–
polyacrylamide gel electrophoresis in tris/glycine buffer,
transferred to nitrocellulose blotting membrane, blocked for
20 min, and blotted with all primary antibodies diluted
(1:1000) except GAPDH (1:2000) in blocking buffer overnight
at 4°C. After 3 times of washing in TBS containing 0.1%
Tween20, the membrane was incubated in secondary anti-
body diluted with TBS containing 0.1% Tween20 for 1 h and
washed mentioned earlier above, and the protein was de-
tected using the ChemiDoc MP Imaging System (Bio-Rad, Her-
cules, CA). The proteins of interest were analysed using
Image Lab 6.0 (Bio-Rad, Hercules, CA), and the protein inten-
sities were quantiﬁed using NIH ImageJ software. GAPDH was
used as an internal standard unless otherwise speciﬁed to
quantify western blot bands.
Section and staining
For immunohistochemical staining, tissues were ﬁxed in 10%
formalin, embedded in parafﬁn, and cut into 6 μm sections
on slides. The slides were incubated with the 1:250 diluted
anti-UCP1 antibody and the 1:50 diluted anti-SIRPα antibody.
Frozen cryosections (8 μm) of TA from control and CKD mice
were mounted on glass slides (Zhang et al., 2010). After the
immunostaining with anti-laminin, the myoﬁber sizes were
analysed using NIS-Elements Br 3.0 software (Nikon). For Oil
Red O staining, adipocyte cells were washed with PBS and
ﬁxed in 4% paraformaldehyde for 1 h at room temperature.
After being washed with PBS, the cells were stained with a
0.2% Oil Red O solution for 15 min. Images were processed
using a Nikon 80i microscope (Melville, NY).
Human study
Biopsies of fat and muscle were obtained from healthy sub-
jects during abdominal hernia surgeries. Serum samples
from healthy controls were obtained from blood donors.
Serum samples and biopsies of fat and muscle from CKD pa-
tients were obtained prior to peritoneal dialysis catheter
placement. The rectus abdominis muscle and periumbilical
fat were biopsied, and cDNA isolated or biopsy samples
were frozen at 80°C or ﬁxed in 10% formalin, embedded
in parafﬁn, and stored until analysed. Informed consent
was obtained and possible consequences of the studies
were explained to all participants. The procedures were
approved by the Ethics Committee of the Department of In-
ternal Medicine of the University of Genoa, in accordance
with the Declaration of Helsinki regarding ethics of human
research.
Role of SIRPα in cachexia 1213
DOI: 10.1002/jcsm.12459
Journal of Cachexia, Sarcopenia and Muscle 2019; 10: 1210–1227
Statistical analysis
Values are expressed as mean ± SEM. Signiﬁcant analysis was
performed using two-tailed unpaired t-test for single vari-
ables and for multiple variables by analysis of variance
followed by Bonferroni test. P < 0.05 was considered statisti-
cally signiﬁcant. GraphPad Prism software was used for
statistical analysis.
Results
Signal regulatory protein alpha deletion prevents
chronic kidney disease-induced muscle protein
wasting
In the present experiments, we explored mechanisms by
which SIRPα contributes to the development of cachexia
by characterizing WT mice with CKD. These mice had BUN
values and body weight losses similar to those of responses
that occur in patients with advanced CKD (Figure 1A and
1B). Mice with CKD lost lean body and muscle mass plus re-
duced grip strength vs. results from WT, sham-operated,
control mice (Figure 1C–E). In contrast, global KO of SIRPα
mutant (Mt) mice with CKD exhibited improvements in body
weight, lean body mass, and muscle mass despite a similar
level of azotemia. The SIRPα Mt mice with CKD also had sig-
niﬁcantly stronger grip strength (P < 0.05) than WT mice
with CKD (Figure 1D). The responses were conﬁrmed when
we analysed myoﬁbers: there was a rightward shift of
cross-sectional areas of myoﬁbers in TA muscles (Figure
1F). SIRPα absence also improved intracellular insulin signal-
ling in muscles (Figure S1A) and there was no enhancement
of the expression of IL-6 or atrophy-related genes (e.g.
MuRF1, Atrogin-1, and MSTN; Figure 1G). In contrast, WT
mice with CKD developed a ﬁve-fold increase in SIRPα ex-
pression and increased the expressions of atrophy-related
genes (Figure 1G). In the present experiments, these
changes in muscle metabolism were associated with a 31%
survival advantage of the SIRPα Mt mice with CKD vs. the
survival of WT mice with CKD (Figure 1H).
Signal regulatory protein alpha knockout improves
chronic kidney disease-impaired insulin signalling in
adipose tissues
In WT mice, we conﬁrmed that CKD reduces glucose and insu-
lin tolerances (Figure 2A and 2B) and impairs the metabolism
of adipose tissue. Speciﬁcally, in WT mice with CKD, epididy-
mal white adipose tissue (eWAT; Figure 2C) and inguinal WAT
(iWAT; Figure S2A) exhibited tyrosine dephosphorylation of
IRS1. These responses were associated with impaired insulin
signalling and decreased pAkt (Figures 2C and S2A). In
contrast, SIRPα Mt mice had improved insulin and glucose
tolerance vs. WT mice even when the mice had CKD
(Figure 2A and 2B). Moreover, WAT of SIRPα Mt mice with
CKD exhibited improved insulin signalling, with an increase
in levels of pAkt plus phosphorylation of tyrosines in IRS1
(Figures 2C and S2A). The striking differences in responses
to WT and SIRPα Mt mice included a signiﬁcantly higher
level of tyrosine phosphatase activities in WT mice with
CKD (Figure 2D and 2E). While SIRPα Mt mice with CKD
exhibited blunting of tyrosine phosphatase activity despite
CKD (Figure 2D and 2E).
We also studied primary cultures of white adipocytes ob-
tained from WT or SIRPα Mt mice. Lipid accumulation in
cells from SIRPα Mt mice was reduced compared with re-
sults from WT mice. Insulin administration stimulated lipid
accumulation in WT adipocytes; this response was blunted
in adipocytes of SIRPα Mt mice treated with insulin
(Figure 2F). Besides these results from primary cultures of
adipocytes, there was lipid accumulation in livers of WT
mice with CKD vs. results from cells of SIRPα Mt mice with
CKD (Figure S2B). In addition, serum levels of cholesterol
and triglycerides in WT mice with CKD were increased vs.
results from SIRPα Mt mice with CKD (Figure 2G). Thus,
SIRPα elimination in mice with CKD prevents the develop-
ment of insulin resistance and changes in lipid metabolism
that occurs in patients with metabolic syndrome.
Suppressed signal regulatory protein alpha
promotes white adipose tissue browning
independently of parathyroid hormone
We hypothesized that the reduction in lipid accumulation in
SIRPα Mt mice may be related to browning of WAT. Based
on indirect calorimetry, VO2 consumption was higher in
WT mice with CKD vs. SIRPα Mt mice with CKD (Figure
S3A). In addition, the CO2 production, the RER, and heat
generation were all signiﬁcantly higher in WT mice
with CKD vs. SIRPα Mt mice with CKD (Figure S3B–D). These
responses were not due to differences in physical activity
(Figure S3E).
It has been reported that WAT browning plays an impor-
tant role in causing muscle protein wasting. Kir et al.
noted that increased levels of PTH in WT CKD mice were as-
sociated with browning of WAT, and these in turn led to ac-
tivation of muscle protein degradation.16 We evaluated the
role of PTH in the mice we studied. We found that plasma
levels of PTH were increased in WT mice with CKD but sup-
pressed in SIRPα Mt mice with CKD (Figure 3A). These re-
sponses were not associated with changes in serum
calcium (Figure 3B). However, in SIRPα Mt mice with or
without CKD, both eWAT and iWAT underwent browning
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Figure 1 Absence of SIRPα suppresses CKD-induced muscle wasting. At 12–16 weeks after subtotal nephrectomy (A–G: n = 4–6mice/group): (A) blood
urea nitrogen (BUN) and body weight (B) were measured. (C) Lean mass was measured by dual-energy X-ray absorptiometry (DEXA) and (D) grip
strength in Newton (N) was determined. (E) Weight (Wt) of gastrocnemius (Gas) muscles was determined and normalized to tibia length (TL). (F) Cryo-
sections of TA muscles were immunostained with anti-laminin (red) to assess myoﬁber sizes (scale bar = 100 μm). Myoﬁber areas were measured, and
the distribution of areas of 500myoﬁbers was assessed by a blinded observer. (G) mRNAs from gas skeletal muscles were determined by RT–qPCR. (A–
G) Values are expressed as mean ± SEM; *P < 0.05, sham vs. CKD and #P < 0.05, WT vs. SIRPα Mt mice. (H) Survival was calculated from the percent-
age of mice surviving at 2 weeks after creating CKD [n = 5–7 sham, n = 20–22mice per CKD group, log-rank (Mantel–Cox) test, P values illustrated]. See
also Figure S1.
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Figure 2 Suppressing SIRPα improves insulin signalling in white adipose tissue (WAT) and lipid deposition. Insulin sensitivity in mice after a 16 h fast
was determined by (A) following intraperitoneal glucose (1.5 g/kg). (B) Intraperitoneal insulin (0.75 U/kg) tolerance was measured after a 4 h fast. (C)
Protein lysates of epididymal white adipose tissue (eWAT) were immunoblotted to detect SIRPα, pIRS1, IRS1, and pAkt (Ser473), Akt and GAPDH (left
panel) and the relative densities to GAPDH or pAkt to Akt ratios are shown (right panel). (D and E) Tyrosine phosphatase activity was measured in
eWAT or inguinal white adipose tissue (iWAT). (F) Primary cultures of inguinal adipocytes from WT vs. SIRPα Mt mice were treated with or without
insulin and stained for Oil Red O (scale bar = 100 μm). (G) Serum cholesterol and triglyceride levels were measured (A–G; n = 4–6 mice/group). Values
are expressed as mean ± SEM; *P < 0.05, sham vs. CKD and #P < 0.05, WT vs. SIRPα Mt mice. See also Figure S2.
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Figure 3 The absence of SIRPα promotes thermogenic genes, independently of parathyroid hormone (PTH). (A) Plasma PTH and (B) serum calcium
levels were measured. (C) eWAT and (D) iWAT are pictured (scale = 1 cm). Tissue weight from (E) eWAT and (F) iWAT is illustrated. mRNA levels of
(G) eWAT and (H) iWAT were determined by RT–qPCR analysis. (I) Protein lysates from eWAT and (J) iWAT samples were immunoblotted for UCP1,
PPARγ, and GAPDH. Immunohistochemical staining for UCP1 protein was performed on (K) eWAT and (L) iWAT (scale bar = 100 μm) (A–L: n = 4–6
mice/group). Values are expressed as mean ± SEM; *P < 0.05, sham vs. CKD and #P < 0.05, WT vs. SIRPα Mt mice. See also Figure S3.
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(Figure 3C and 3D). In SIRPα Mt mice, fat mass was pre-
served compared with values in WT mice with CKD (Figure
3E and 3F). Interestingly, WT mice with CKD or SIRPα Mt
mice with or without CKD exhibited increases in thermo-
genic genes (e.g. UCP1, PGC1α, and CIDEA) (Figure 3G and
3H). Notably, mRNAs of these genes were associated with
up-regulation of UCP1 and PPARγ proteins in both eWAT
or iWAT of WT mice with CKD. Similar responses occurred
in SIRPα Mt mice with or without CKD (Figures 3I–L and
S3F–G). Thus, browning of WAT isolated from SIRPα Mt
mice with CKD was not stimulated by PTH and did not in-
crease VO2 consumption or heat generation. There also
was no evidence indicating ubiquitin proteasome system
(UPS) activation nor loss of muscle mass (Figure 1C–G).
In chronic kidney disease, signal regulatory protein
alpha suppression promotes protein kinase
A-independent adipose tissue browning
To determine if WAT browning is controlled by sympathetic
activation of PKA, we examined the inﬂuence of PKA on SIRPα
Mt mice with CKD. Potential stimulators of PKA include an in-
crease in PTH.16 However, our measurements in SIRPα Mt
mice with CKD show that PTH is not elevated (Figure 3A). An-
other mechanism by which CKD could stimulate PKA would
occur with activation of the sympathetic nervous system.16–
18 We found that pPKA was increased in both iWAT and
eWAT of WT mice with CKD vs. results obtained in SIRPα
Mt mice with CKD (Figure 4A and 4B). Moreover, adipocytes
Figure 4 PKA activity and its mediators are suppressed in SIRPα Mt Mice with CKD. (A–B) eWAT and iWAT protein lysates were immunoblotted to
detect phosphorylated protein kinase A [pPKA (RRXS/T)], pHSL, pCREB, and GAPDH (top panel); and the relative densities to the level of GAPDH are
shown (bottom panel). (C) PKA activity assay was determined in eWAT (A–C: n = 4–6 mice/group). Values are expressed as mean ± SEM; *P <
0.05, sham vs. CKD and #P < 0.05, WT vs. SIRPα Mt mice.
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from WT mice with CKD displayed increased expression of
mediators of browning, namely, pHSL and pCREB. The same
pathways were signiﬁcantly reduced in SIRPα Mt mice with
CKD. Notably, in WT mice with CKD, PKA activity in eWAT
was signiﬁcantly higher vs. the level in SIRPα Mt mice with
CKD (Figure 4C). We conclude that WAT browning in WT mice
with CKD develops as a result of a PKA-dependent response.
In contrast, browning of WAT in SIRPα Mt mice did not de-
pend on activation of PKA or its mediators.
Protein kinase A activation of cAMP response
element-binding protein to signal regulatory
protein alpha interferes with insulin signalling
CREB binding sites are found in the SIRPα promoter (http://
natural.salk.edu/CREB/), whether CREB activation regulates
SIRPα functions is largely unknown. We activated CREB by
adding forskolin (FSK) to 3T3-L1 adipocytes and found that
the expressions of pCREB, SIRPα, pHSL, and UCP1 increased
while pAkt was reduced (Figure 5A). When we treated 3T3-
L1 adipocytes with the CREB inhibitor, 666-15, we found re-
duced expressions of pCREB, SIRPα, and UCP1 but no change
in the level of pHSL or pAkt (Figure 5B). These results raise
the possibility that PKA activates CREB, which stimulates
SIRPα expression. To determine how SIRPα expression occurs,
we injected WT and SIRPα Mt mice with 1 mg/kg of norepi-
nephrine (NE). Western blotting of NE-stimulated WAT from
WT mice revealed signiﬁcant increases in the expressions of
SIRPα, pCREB, and pHSL plus the thermogenin gene (Figure
5C). In addition, we found decreased expression of pAkt at
6 h after NE treatment but not at 2 h (Figures S4A and 5C).
Interestingly, treatment of SIRPα Mt mice with NE not only
suppressed pAkt, pHSL, and pCREB but also blocked UCP1 ac-
tivation (Figures 5C and S4B). We conclude that browning
was reduced in SIRPα Mt mice treated with NE; the mecha-
nism may be due to a reduction in pAkt. Moreover, WAT
treatment with NE led to increases in PKA activity in primary
cell cultures of WAT from WT mice. In contrast, PKA activity
was suppressed in primary cell cultures of WAT from SIRPα
Mt mice that were treated with NE (Figure S4B).
To determine if similar events regulate UCP1 expression,
we studied primary cell cultures of WAT obtained from WT
or from SIRPαMt mice. When either of the primary cells were
treated with the PI3K inhibitor, LY294002, pAkt was sup-
pressed, but the expressions of SIRPα, pHSL, pCREB, and
UCP1 were increased (Figure 5D). Adipocytes from SIRPα Mt
mice treated with the PI3K inhibitor led to suppression of
UCP1 expression. The results suggest that reduced pAkt con-
tributes in a major way to the browning of WAT obtained
from SIRPα Mt mice (Figure 5D). When we treated cultured
adipocytes from WT or SIRPαMt mice with the PI3K inhibitor,
we found an increase in the activation of PKA in WAT from
WT adipocytes (Figure S4C). Next, we transfected 3T3-L1 ad-
ipocytes with a plasmid that overexpresses SIRPα. In this
case, levels of pHSL, pCREB, and UCP1 were up-regulated
which was associated with a suppression of pAkt (Figure
5E). Additionally, when SIRPα was overexpressed, PKA activa-
tion was stimulated (Figure S4D). These responses cause an
increase in UCP1 and pathologic browning of WAT.
In the cachexia of acute diabetes, white adipose
tissue browning is protein kinase A dependent
To test if the responses we identiﬁed were suggestive of in-
creased insulin levels alone, we utilized another model of ca-
chexia, STZ treatment. STZ is characterized by loss of
gastrocnemius muscle and WAT adipocytes.19 Metabolic re-
sponses to STZ treatment included the development of
insulinopenia and hyperglycaemia in WT and SIRPα Mt mice
(Figure S5A and B). In SIRPα Mt mice, the loss of gastrocne-
mius and WAT weights was ameliorated despite the presence
of acute diabetes and a suppressed level of insulin (Figure
S5C). In addition, grip strength in acutely diabetic WT mice
exhibited signiﬁcant impairment vs. results from the acutely
diabetic SIRPα Mt mice (Figure S5D; P < 0.05). There also
were increases in the expressions of autophagy genes (e.g.
ATG12, BECN1, LC3, and p62) in WT, STZ-treated mice (Figure
S5E). Acutely diabetic SIRPα Mt mice did not express the
same autophagy genes that were signiﬁcantly suppressed
vs. results from acutely diabetic WT mice (Figure S5E; P <
0.05). Notably, SIRPα was increased in both eWAT and iWAT
of acutely diabetic WT mice, and there was evidence for im-
pairment in intracellular insulin signalling plus activation of
UCP1 (Figure S5F and G). In gastrocnemius muscles from
acutely diabetic WT mice, pAkt was reduced but SIRPα ex-
pression was increased (Figure S5H). We also found activation
of pPKA, pHSL, and pCREB in eWAT and iWAT (Figure S5I and
J). Conversely, in acutely diabetic SIRPα Mt mice, pAkt levels
in WAT were similar to those in control mice. UCP1 remained
high in both groups. Notably, the levels of pPKA, pHSL, and
pCREB were suppressed in acutely diabetic SIRPα Mt mice
in comparison with acutely diabetic WT mice (Figure S5I
and J). On the basis of these results, we conclude that
blocking SIRPα improves the metabolism of muscle protein
and adipocytes in acute diabetes. This promotes physiologic
browning via a pathway that does not require activation of
PKA or PKA mediators.
Muscle-speciﬁc suppression of signal regulatory
protein alpha improves insulin signalling and
prevents cachexia in chronic kidney disease
Skeletal muscle-speciﬁc SIRPα KO (mSIRPα/) mice were
created by crossing Mck-Cre mice with mice bearing ﬂoxed
exons 3–4 of SIRPα. Both SIRPα ﬂox/ﬂox(ﬂ/ﬂ) and mSIRPα/
mice were treated to produce CKD and compared. The two
groups of mice displayed signiﬁcant (P < 0.05) elevations in
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Figure 5 PKA activates CREB, stimulating SIRPα and interfering with insulin signalling. (A) 3T3-L1 adipocytes were treated with forskolin (FSK, 10 μM)
for 24 h, and lysates immunoblotted (left panel) for relative densities to GAPDH or pAkt to AKT are shown (right panel) for SIRPα, pHSL, pCREB, pAkt
(Ser473), Akt, and UCP1 (n = 4 independent experiments). (B) 3T3-L1 adipocytes were treated for 24 h with 50 nM CREB inhibitor (compound 666-15)
and lysates were immunoblotted (left panel) for SIRPα, pHSL, pCREB, pAkt (Ser473), Akt, UCP1, and GAPDH, and relative densities to GAPDH or pAkt to
AKT are shown ( right panel; n = 4 independent experiments). (C) Mice treated with 1mg/kg noradrenaline bitartrate (NE) for 2 h were compared with
vehicle-treated mice. iWAT was homogenized and immunoblotted (left panel) for SIRPα, pHSL, pCREB, pAkt (Ser473), Akt, and UCP1, and relative den-
sities that obtained to GAPDH or pAkt to AKT are shown (right panel; n = 4–6 mice/group). (D) Primary cultures of iWAT from WT or SIRPα Mt mice
were treated with or without a PI3K inhibitor (PI3Ki) at 50 μM for 6 h. Lysates from these cells were immunoblotted (left panel) for SIRPα, pHSL, pCREB,
pAkt (Ser473), Akt, and UCP1; and relative densities obtained to GAPDH or pAkt to AKT are shown (right panel; n = 4 independent experiments). (E)
3T3-L1 adipocytes were transfected with a plasmid stimulating SIRPα expression and compared with results from a plasmid that expresses green ﬂuo-
rescent protein (GFP). Lysates were immunoblotted (left panel) for SIRPα, pHSL, pCREB, pAkt (Ser473), Akt, and UCP1; and relative densities obtained
to GAPDH or pAkt to AKT are shown (right panel; n = 4 independent experiments). Values are a mean ± SEM. (A–B, E) *P < 0.05, control vs. treatment.
(C–D) *P < 0.05, control vs. treatment and #P < 0.05, WT vs. SIRPα Mt mice. See also Figure S4.
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Figure 6 Blocking SIRPα in muscle facilitates inter-organ communication and prevents cachexia in CKD. At 8–12 weeks after subtotal nephrectomy (A–
G: n = 4–6mice/group): (A) blood urea nitrogen (BUN), (B) grip strength, (C) glucose tolerance, and (D) insulin levels were measured by ELISA. (E) Organ
harvest weight normalize to tibia length (TL) was measured. (F) Protein lysates of gastrocnemius (Gas) skeletal muscle were immunoblotted (top panel)
to detect SIRPα, pAkt (Ser473), and GAPDH; and relative densities were measured (bottom panel). (G) Inguinal white adipose tissue (iWAT) was
immunoblotted (top panel) to detect SIRPα, pCREB, pAkt (Ser473), UCP1, phosphorylated protein kinase A [pPKA (RRXS/T)], and relative
densities obtained to GAPDH are shown (bottom panel). (H) ELISA was performed to detect circulating serum levels of SIRPα. Values are expressed
as mean ± SEM; *P < 0.05, sham vs. CKD and #P < 0.05, SIRPαﬂ/ﬂ vs. mSIRPα/.
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BUN (Figure 6A). Additionally, SIRPαﬂ/ﬂ mice with CKD exhib-
ited reduced grip strength compared with results from
mSIRPα/ mice that also had CKD (Figure 6B). Glucose toler-
ance was improved in mSIRPα/ compared with SIRPαﬂ/ﬂ
mice (Figure 6C). Importantly, SIRPαﬂ/ﬂ mice with CKD had ev-
idence of hyperinsulinaemia (5.2-fold higher) as compared
with normal insulin levels in mSIRPα/ mice with CKD (Fig-
ure 6D). Weights of WAT and gastrocnemius, TA, EDL, and so-
leus skeletal muscles were all decreased in SIRPαﬂ/ﬂ mice with
CKD vs. measurements from mSIRPα/ mice with CKD (Fig-
ure 6E). Thus, mSIRPα/ mice with CKD have preservation
of the weight of WAT and skeletal muscles compared with re-
sults from SIRPαﬂ/ﬂ mice with CKD. We explored the mecha-
nisms for these responses by measuring insulin signalling in
both WAT and skeletal muscles. In skeletal muscle,
mSIRPα/ mice with CKD exhibited improved intracellular
insulin signalling with increased levels of pAkt. In contrast,
WAT displayed increased expression of SIRPα. In this case,
we found that intracellular insulin signalling in skeletal muscle
and WAT improved in mSIRPα/ mice, despite the presence
of CKD (Figure 6F and 6G). Notably, pathologic browning was
present in WAT of SIRPαﬂ/ﬂ mice with CKD. In the mSIRPα/
mice with CKD, we found up-regulation of UCP1 plus suppres-
sion of activated pPKA and its mediators (Figure 6G). These
responses suggest the presence of physiologic browning.
Consistent with this formulation, we ﬁnd evidence of in-
creased circulating levels of SIRPα in serum of SIRPαﬂ/ﬂ mice
with CKD (Figure 6H). This result suggests that SIRPα may
be a mediator of inter-organ communication. Therefore,
crosstalk between skeletal muscles and WAT includes our
ﬁnding that elimination of SIRPα in muscle unexpectedly
improved insulin sensitivity and led to physiologic browning
in WAT without loss of skeletal muscles plus diminished loss
of WAT.
Adipose-speciﬁc signal regulatory protein alpha
knockout with chronic kidney disease displayed
improved insulin signalling but did not prevent
dyslipidaemia or losses of skeletal muscle
We evaluated whether there is inter-organ communication
between adipose tissue and skeletal muscle by creating
adipose-speciﬁc SIRPα KO (AD-SIRPα/) mice on the basis
of methods similar to those we used in obtaining mSIRPα/
 mice. We used adiponectin-Cre to delete SIRPα ﬂoxed
exons 3–4 speciﬁcally in adipose tissues. Initially, we com-
pared results of glucose tolerance testing in SIRPαﬂ/ﬂ and
AD-SIRPα/ mice with CKD (Figure 7A). There were similar
levels of circulating insulin in SIRPαﬂ/ﬂ mice with CKD and
AD-SIRPα/ mice with CKD (Figure 7B); both insulin values
were higher than those present in mSIRPα/ mice with
CKD (Figure 6D). With CKD, serum cholesterol in both
SIRPαﬂ/ﬂ mice and AD-SIRPα/ mice was not different
(Figure 7C). However, grip strength of AD-SIRPα/mice with
CKD was greater compared with results from SIRPαﬂ/ﬂ mice
with CKD (Figure 7D). Upon harvest, AD-SIRPα/ mice with
CKD exhibited preservation of WAT weight plus improved in-
sulin signalling and physiologic browning of WAT (Figure 7E
and 7F). These responses occurred without evidence of PKA
activation (Figure 7F). In skeletal muscles, AD-SIRPα/ mice
with CKD exhibited no statistically signiﬁcant improvement
in weight of the gastrocnemius, TA, and soleus (Figure 7E)
with evidence of SIRPα up-regulation in gastrocnemius skeletal
muscle despite improvements in activation of pAkt (Figure 7F).
Finally, serum SIRPα levels in SIRPαﬂ/ﬂ mice with CKD were
increased and remained elevated in AD-SIRPα/ mice with
CKD (Figure 7G). These results are consistent with a communica-
tion between skeletal muscles and adipose tissues regulated by a
novel mediator of insulin resistance, activated by SIRPα.
Signal regulatory protein alpha and white adipose
tissue browning are increased in patients with
chronic kidney disease
We examined biopsies of rectus abdominis muscles and
periumbilical WAT obtained from control adults and patients
with advanced CKD, characterized by increased C-reactive
protein and serum creatinine (Table S1A). In muscles of CKD
patients, we detected increased mRNAs of SIRPα, IL-6, and at-
rophy genes (Atrogin-1 and MuRF1): these values were com-
pared with those present in control adults (Figure 8A).
Likewise, skeletal muscle SIRPα levels in patients with CKD
were increased vs. values in control subjects (Figure 8B and
8C). When we examined measurements in those subjects
with CKD, we found that there were higher mRNA levels of
SIRPα and UCP1, indicating WAT browning vs. levels in con-
trol adults (Figure 8D). Immunohistochemical staining of
WAT from CKD patients uncovered higher levels of SIRPα plus
UCP1 proteins (Figure 8E-F). These increases in SIRPα expres-
sion and markers of browning in WAT of CKD patients were
associated with weight loss (Table S1A). Finally, serum SIRPα
was increased 2.4-fold in patients with advanced CKD when
compared with healthy controls (Figure 8G, Table S1B).
Discussion
In investigating mechanisms causing cachexia in mice with
CKD or acute diabetes, we have determined that endogenous
SIRPα expression is of primary importance for several rea-
sons: (i) SIRPα in mice with CKD is highly expressed in skeletal
muscles and adipocytes, leading to impaired insulin signalling
mediated by SIRPα. (ii) We identiﬁed that PKA activation pro-
motes SIRPα expression and, hence, can be a mediator of the
development of cachexia and pathologic browning of WAT.
These responses resulted in decreased intracellular insulin
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signalling including a reduction in pAkt. (iii) We ﬁnd that mice
with global suppression of SIRPα exhibited improved insulin
signalling and promotion of physiologic browning of WAT
via a PKA-independent pathway. In mice with CKD, the
distinguishing feature of physiologic browning is suppression
of SIRPα plus improved insulin sensitivity resulting in up-
Figure 7 Blocking SIRPα in adipose tissue does not lead to signiﬁcant inter-organ communication or prevention of cachexia (A–G: n = 4–6mice/group).
(A) Glucose tolerance, (B) insulin levels, (C) serum cholesterol, and (D) grip strength were measured. (E) Organ harvest weight was measured. (F) Pro-
tein lysates of inguinal and epididymal white adipose tissue (iWAT/eWAT) were immunoblotted (left panel) to detect phosphorylated protein kinase A
[pPKA (RRXS/T)], SIRPα, pAKT (Ser473), pCREB, UCP1, and GAPDH. Protein lysates of gastrocnemius skeletal muscle were immunoblotted (left panel) to
detect either SIRPα or pAkt (Ser473), and relative densities obtained to GAPDH are shown (right panel). (G) Serum SIRPα was measured by immuno-
blot. Values are expressed as mean ± SEM; *P < 0.05, sham vs. CKD and #P < 0.05, SIRPαﬂ/ﬂ vs. AD-SIRPα/.
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regulation of pAkt in WAT as well as improvements in GTT and
ITT. (iv) Notably, SIRPα is highly expressed in acute diabetes,
and it is also associated with pathologic browning of WAT.
(v) We ﬁnd that SIRPα elimination extends the survival of mice
with CKD. (vi) Skeletal muscle-speciﬁc or adipose-speciﬁc KO
of SIRPα in mice with CKD leads to improved insulin signalling
in both muscles and adipose tissues. Only mice with muscle-
speciﬁc SIRPα KO exhibited suppression of serum insulin and
circulating levels of SIRPα. These responses lead to minimized
loss of adipose tissue but no loss of skeletal muscle despite
the presence of CKD (Figure 9). Potentially, our ﬁndings sug-
gest that SIRPα exhibits an important, myokine-like response
Figure 8 Patients with CKD expressed up-regulation of SIRPα, atrophy-related genes and browning of WAT (n = 7–9 patients/group). (A) mRNAs of
skeletal muscles were determined on the basis of RT–qPCR analysis. (B) Immunostaining of muscle sections for SIRPα (see arrows) from biopsies of
age-matched, healthy control subjects and CKD patients. (C) Skeletal muscle lysates were immunoblotted (top panel) for SIRPα; and relative densities
obtained to GAPDH are shown (bottom panel). (D) mRNAs of white adipose tissue (WAT) samples were determined on the basis of RT–qPCR analysis.
Immunostaining of WAT sections for (E) SIRPα (see arrows) and (F) UCP1 (see arrows) was performed on healthy control subjects and CKD patients
(scale bar = 100 μm). (G) Serum was obtained from patients with CKD vs. healthy controls, and ELISA was performed to detect circulating serum levels
of SIRPα (n = 21–29 patients/group). Values are mean ± SEM. *P < 0.05 vs. control. See also Table S1.
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mediating cachexia in mice with CKD while raising the possibil-
ity of crosstalk between adipose tissues and skeletal muscles.
A prominent feature of our results is the development of
pathologic browning of adipose tissue. In WT mice with
CKD, browning was associated with increased energy expen-
diture and thermogenesis (Figure S3A–D). But when SIRPα is
suppressed in mice with CKD, insulin signalling improves,
and there were no signiﬁcant increases in oxygen consump-
tion, the RER, or thermogenesis. The absence of SIRPα im-
proved insulin signalling and also prevented losses of body
and muscle weight as well as adipocyte tissue mass. Interest-
ingly, expression of UCP1 during physiologic browning was
not associated with thermogenesis. We speculate that the
mechanism for this response reﬂects suppressed activation
of PKA (Figure 4A–C).
Recently, a novel mechanism was described to explain the
development of cachexia in mice with CKD or cancer.16,20 In
these models, the anti-catabolic mechanism consists of
interrupting the PTH receptor, preventing losses of muscle
and adipose tissues. But when PKA was stimulated by PTH
or the sympathetic nervous system was activated, cachexia
developed. The authors noted that a high level of circulating
PTH triggered pathologic browning, which stimulated loss of
muscle proteins. Our ﬁndings differ: SIRPα Mt mice
exhibited improved insulin signalling and WAT browning and
experienced no loss of muscle mass. Speciﬁcally, we
found that SIRPα elimination stimulated UCP1 expression
and WAT browning by a mechanism that was independent
of PTH or PKA activation. Also, global KO or muscle and
adipose-speciﬁc KO of SIRPα exhibited improved insulin
sensitivity (e.g. improved GTT plus increased pAkt expression
in WAT and muscle), despite the presence of CKD. Finally, in
mice with either CKD or acute diabetes, cachexia was medi-
ated by PKA stimulation of SIRPα, promoting impaired insulin
signalling.
Regarding the shortcomings of our studies, we recognize
that SIRPα is a membrane-bound protein. Therefore, we hy-
pothesize that inter-organ communication between skeletal
muscles and adipose tissues is due to circulating SIRPα, but
it is unclear if it is behaving as a myokine or related to macro-
phage circulation. For example, Willingham et al. suggests
that macrophages express SIRPα protein.21 To examine circu-
lating factors or the role of macrophage expression of SIRPα
is beyond the scope of these experiments but requires fur-
ther investigation.
Browning of WAT can be promoted by myostatin inhibition
in mice fed a high fat diet.22 Moreover, inhibition of
myostatin in mice with CKD promotes insulin sensitivity and
increases muscle mass.5 In muscles of SIRPα Mt mice with
CKD, myostatin and IL-6 production were suppressed in skel-
etal muscles (Figure 1G). Additionally, Kong et al. found that
increased expression of IRF4 in brown adipocytes participates
in suppressing myostatin and increasing exercise capacity in
skeletal muscles.23 This is relevant because global KO of SIRPα
suppresses myostatin expression while improving muscle pro-
tein losses in CKD.
Bostrom et al., reported that PGC1α overexpression stimu-
lates a myokine, irisin, which promoted the conversion of
white to brown adipocytes.24 As WAT in SIRPα Mt mice with
CKD developed increased grip strength plus up-regulation of
Figure 9 Summary diagram. Suppression of SIRPα improves insulin sensitivity leading to skeletal muscle that is resistant to atrophy plus physiologic
browning of white adipose tissue (WAT). Chronic kidney disease (CKD) and acute diabetes stimulates PKA activity, an up-regulation of SIRPα that in-
hibits insulin signalling causing muscle wasting and pathologic browning of WAT.
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UCP1 and PGC1α, we propose that our results suggest the de-
velopment of an ‘exercise-like’ phenotype (Figures 1D and
3G–J) despite lacking signiﬁcant changes in physical activity
(Figure S3E). Peng et al. recently reported that irisin released
from skeletal muscle interacts with injured kidney tubule cells
by improving ATP production and energy metabolism. The re-
sult is more rapid recovery of injured kidney tubular cells.
These ﬁndings suggest that besides muscle and adipocytes,
metabolic responses may change in other organs.25
In summary, SIRPα is a novel regulator of lost muscle
protein and adipose tissues in two models of cachexia,
CKD and acute diabetes. We have found evidence for
increased expression of SIRPα and UCP1 in adipose tissues
plus increased SIRPα in skeletal muscles and serum samples
of patients with advanced CKD. These ﬁndings could lead to
potential therapeutic targets for combating cachexia in con-
ditions of CKD and type 1 diabetes while promoting survival
in patients suffering from these catabolic illnesses.
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Table S1. Characteristics of Patients with CKD and Age
Matched Healthy Controls. (Related to Fig. 8) (A) Patient
characteristics deﬁned from skeletal muscle and adipose tis-
sue biopsies (n = 7-9 patients/group). Values are a mean
±SEM. *p < 0.05 vs. Control. (B) Serum was obtained from
patients with CKD vs. healthy controls and their known char-
acteristics are deﬁned. (n = 21-29 patients/group).
Figure S1. Suppression of SIRPα Improves Intracellular Insulin
Signaling in Skeletal Muscles of Mice with CKD. (Related to
Fig. 1). (A) Gastrocnemius (Gas) lysates were immunoblotted
for SIRPα, GLUT4, pAkt (ser 473), and GAPDH. (n = 4-6
mice/group).
Figure S2. Blocking SIRPα in Mice with CKD Improves Insulin
Intracellular Signaling and Ectopic Lipids. (Related to Fig. 2).
(A) iWAT lysates were immunoblotted for SIRPα, pAkt (ser
473), Akt, and GAPDH. (B) Lipid content in liver was mea-
sured. (A-B: n = 4-6 mice/group). Values are expressed as
mean±SEM; *p < 0.05, Sham vs. CKD and #p < 0.05, WT
vs. SIRPα Mt mice.
Figure S3. The Absence of SIRPα Did Not Generate Heat or Ex-
pend Energy Despite the Presence of CKD. (Related to Fig. 3).
(A-E) VO2, CO2, Respiratory Exchange Ratio, Heat, and Phys-
ical Activity were monitored by indirect calorimetry. (F) eWAT
and (G) iWAT lysates were immunoblotted for UCP1, PPARγ
and GAPDH and the relative band densities to GAPDH are
shown. (A-G: n = 4-6 mice/group). Values are expressed as
mean±SEM; *p < 0.05, Sham vs. CKD and #p < 0.05, WT
vs. SIRPα Mt mice.
Figure S4. Stimulation of PKA Downregulates Intracellular In-
sulin Signaling. (Related to Fig. 5).(A) White adipocytes were
treated with or without norepinephrine (NE) for 6 h and ly-
sates were immunoblotted for pAkt, Akt, and GAPDH. (B) Pri-
mary cultures of iWAT were treated with or without insulin 1
nM for 10 minutes or the PI3K inhibitor (LY294002) 50 μM,
norepinephrine (NE) 100 nM, H89 50 μM for 30 min and ly-
sates were immunoblotted for phosphorylated protein kinase
A (pPKA (RRXS/T)) and GAPDH. (C) Primary cultures of iWAT
from WT or SIRPα Mt mice were treated with or without a
PI3K inhibitor at 50 μM for 6 h and lysates were
immunoblotted for pPKA (RRXS/T) and GAPDH. (D) 3T3-L1 ad-
ipocytes were transfected with a SIRPα plasmid stimulating
PKA expression and compared to results from a plasmid that
expresses green ﬂuorescent protein (GFP). Lysates were
immunoblotted for pPKA (RRXS/T) and GAPDH (n = 3 inde-
pendent experiments).
Figure S5. Blocking SIRPα Prevents Acute Diabetes-Induced
Cachexia. (A) Mice were treated with streptozotocin (STZ)
to create insulinopenia. (B) Hyperglycemic streptozotocin
(STZ)-treated mice were studied. (C) Organ weights (Wt) were
normalized to tibia length (TL). (D) Grip strength in Newtons
(N) was determined. (E) mRNA levels of autophagy genes in
gastrocnemius skeletal muscle were measured using RT-
qPCR analysis. (F) eWAT and (G) iWAT (H) Gastrocnemius
(Gas) lysates were immunoblotted (top panel) for SIRPα, pAkt
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(ser 473), Akt, UCP1 and GAPDH. The relative band densities
to GAPDH or pAkt to Akt are shown (bottom panel). (I) eWAT
and (J) iWAT lysates were immunoblotted (left panel) phos-
phorylated protein kinase A (pPKA (RRXS/T)), pHSL, pCREB,
and GAPDH. The relative band densities to GAPDH were de-
termined (right panel; A-J: n = 4-6 mice/group). Values are a
mean SEM; *p < 0.05, Sham vs. STZ, #p < 0.05, WT vs. SIRPα
Mt.
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